Biologic Drug Product CDMO Benchmarking for Small & New Pharma

Report Overview

ISR’s Biologic Drug Product Contract Manufacturer Quality Benchmarking: A Look at Small & Emerging Biopharma report is an-depth look at a subset of respondents from small and emerging biopharma companies. The findings in this report will help small and emerging biopharmaceutical companies make more informed CMO decisions, and help CMOs optimize operational and marketing strategies to better accommodate this segment.

ISR understands the need for a deeper dive regarding the small and emerging biopharma landscape. This report provides pharmaceutical companies and contract manufacturers a comprehensive analysis of current outsourcing philosophies and practices, CMO selection drivers, and CMO perceptions and interactions. Findings are based on 25 respondents.

What you will learn:

Small & Emerging Drug Developers:

• Make a more educated purchase of CMO services by understanding which manufacturers best fit your company’s needs
• Uncover which CMO attributes drive outsourcing partner selection for outsourced biologic drug product manufacturing as well as which CMO attributes have gained importance over the past 12 months among industry peers
• Understand overall CMO customer loyalty via ratings of customer satisfaction, willingness to recommend, and likelihood to use again

Contract Manufacturers:

• Understand your company’s market awareness and positioning, and use this information to develop targeted messaging to small and emerging biopharma companies
• Gain insight into small and emerging drug developers’ preferences and practices with respect to CMO selection and CMO preference for outsourced biologic drug product manufacturing

Major Topics:

• Outsourcing Philosophies and Practices
• CMO Selection Drivers
• CMO Perceptions and Interactions
• Study Data
• Demographics